KR20020031911A - crude drug for 2type diabetes - Google Patents
crude drug for 2type diabetes Download PDFInfo
- Publication number
- KR20020031911A KR20020031911A KR1020000062697A KR20000062697A KR20020031911A KR 20020031911 A KR20020031911 A KR 20020031911A KR 1020000062697 A KR1020000062697 A KR 1020000062697A KR 20000062697 A KR20000062697 A KR 20000062697A KR 20020031911 A KR20020031911 A KR 20020031911A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- extract
- diabetes
- cordyceps sinensis
- red ginseng
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title description 8
- 239000003814 drug Substances 0.000 title description 6
- 229940079593 drug Drugs 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 49
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 24
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 13
- 229940088594 vitamin Drugs 0.000 claims abstract description 12
- 235000002789 Panax ginseng Nutrition 0.000 claims description 27
- 238000002360 preparation method Methods 0.000 claims description 11
- 240000001439 Opuntia Species 0.000 claims description 7
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 claims description 7
- 241000411851 herbal medicine Species 0.000 claims description 5
- 239000000321 herbal drug Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 239000012674 herbal formulation Substances 0.000 claims 1
- 241000208340 Araliaceae Species 0.000 abstract description 10
- 235000008434 ginseng Nutrition 0.000 abstract description 10
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 9
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract description 3
- 239000013583 drug formulation Substances 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241000190633 Cordyceps Species 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 240000000724 Berberis vulgaris Species 0.000 description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- -1 alloxan Saponin Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003471 anti-radiation Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 2형 당뇨에 효능이 있는 생약제제로 보다 상세하게는 홍삼, 가시오가피, 동충하초의 추출물과 멀티-비타민을 주원료로 한 2형 당뇨 치료에 효능이 있는 생약제제에 관한 것이다.The present invention relates to a herbal drug that is effective for type 2 diabetes, and more particularly, to an herbal drug that is effective for treating type 2 diabetes, which is mainly composed of extracts of red ginseng, barberry, cordyceps and multi-vitamin.
본 발명에서 이용되는 가시오가피는 오가피속에 포함되는 식물 중 하나를 의미하는 것이나, 이하 실시예 등의 중복을 피하기 위하여 가시오가피종만을 대표적으로 언급한다.Prickly Ogapi used in the present invention means one of the plants included in the genus Ogapi, to avoid the duplication of the following examples and the like only representatively refers to prickly Ogapi species.
본 발명은 홍삼, 가시오가피, 동충하초의 잎·줄기 또는 뿌리의 추출물과 멀티-비타민을 주원료로 하고 홍삼, 가시오가피, 동충하초 추출물의 배합비를 달리하여 실험한 결과 2형 당뇨 실험동물인 KKAY마우스에 1달간 경구투여하여 공복시 혈당치를 측정한바 혈당량이 현저하게 감소됨으로써 2형 당뇨병을 치료하는 생약제제를 발명하게된것이다.In the present invention, the extracts of the leaves, stems or roots of red ginseng, spiny gingival and Cordyceps sinensis and multi-vitamin were used as the main ingredients, and the mixing ratios of the extracts of the red ginseng, spiny ginseng and Cordyceps sinensis were tested for 1 month in KKA Y mice, a type 2 diabetic experimental animal. As a result of oral administration of fasting blood glucose levels, blood glucose levels were markedly reduced, leading to the invention of herbal preparations to treat type 2 diabetes.
상기 KKAY마우스란 생물공학적으로 조작하여 유전적으로 2형 당뇨에 걸려있는 실험용 마우스를 말한다. The KKA Y mouse refers to a laboratory mouse genetically manipulated to type 2 diabetes.
당뇨병이란 불연소된 당이 소변으로 배설되는 병으로 의학적으로는 혈중의 당의 농도가 높은 경우에 당뇨병이라고 진단한다. 건강한 사람의 정상적인 혈당수치는 혈액 1데시리터당 80∼120 ㎎으로 이 수치이상의 고혈당 상태가 지속되면 혈액순환이 나빠지고 세포의 손상이 가해지는데, 당뇨에 의한 고혈당은 당의 대사에 관여하는 호르몬인 인슐린이 부족하거나 전혀 생산되지 않는 경우를 1형 당뇨라고 하고, 인슐린이 제대로 분비되어도 불활성화되어 당을 에너지로 바꾸는데 활용되지 못한 경우를 2형 당뇨라고 하는데, 우리 나라 당뇨환자의 90 %가 2형 당뇨의 환자이다.Diabetes is a disease in which unburned sugars are excreted in the urine and medically diagnosed as diabetes when the blood sugar level is high. Normal blood glucose levels in healthy people are 80-120 mg per 1 deciliter of blood. If hyperglycemia above this level persists, blood circulation worsens and cell damage is incurred. Insufficient or not produced at all is called type 1 diabetes, and when insulin is properly secreted, it is inactivated and not used to convert sugar into energy. Type 2 diabetes is known. Patient.
즉, 인슐린이 체내의 혈당량을 조절하는데 있어서, 인슐린의 작용이 정상이면 흡수된 당이 다소 많아도 그 체내 이용을 촉진함으로써 혈당량을 정상적으로 유지할 수 있지만, 인슐린이 활발하지 못한 상태에서는 세포내의 당의 흡수가 정상적으로 이루어지지 못하므로 혈액속의 당이 증가하게 되는 것이다.In other words, when insulin regulates the blood glucose level in the body, if the action of insulin is normal, even though the absorbed sugar is somewhat higher, the blood glucose level can be maintained by promoting the use of the body, but in the state where the insulin is not active, the absorption of the sugar in the cell is normal. Because it is not made, the sugar in the blood will increase.
이와 같은 당뇨병을 치료하기 위하여는 음식섭취로 조절하는 식이요법 및 규칙적이고 적당한 운동을 하는 운동요법을 병행하여 인슐린분비를 촉진하거나, 분비된 인슐린이 정상적으로 작용할 수 있도록 의약품을 복용하거나 인슐린 주사를 맞는 것이 일반적인 치료방법이었다.In order to treat this type of diabetes, a diet controlled by food intake and exercise exercises with regular and moderate exercise may promote insulin secretion, or may take medicine or inject insulin to allow the insulin to function normally. It was a common treatment.
지금까지의 당뇨실험의 경우 사용한 실험동물에 화학물질(STZ, alloxan 등)을투여하여 췌장베타세포에 손상을 입혀 얻은 형태로, 이들은 화학물질을 투여한 용량에 따라 차이가 있기는 하지만 대다수 베타세포의 상당부분이 파괴되어 인슐린 분비능이 거의 없는 제1형 당뇨모델에 가깝다고 할 수 있고 또한 사람의 당뇨병과는 상당한 거리가 있는 모델이었다. 따라서 이러한 질환모델을 이용하여 시료들의 약효를 검색하는 것에는 상당한 오류가 예상되었다.Until now, diabetic experiments have been performed by injecting chemicals (STZ, alloxan, etc.) into the experimental animals used to damage pancreatic beta cells, which are largely dependent on the dose to which the chemicals are administered. It was a model that had been destroyed much of the close to the type 1 diabetes model with little insulin secretion ability, and also a considerable distance from human diabetes. Therefore, a significant error was expected to search for the efficacy of the samples using this disease model.
본 발명에서는 이제까지의 혈당강하 실험의 문제점들을 보완하여 궁극적으로 인슐린저항성을 개선시킴으로써 혈당강하 효능이 뚜렷한 새로운 2형 항당뇨 생약제제를 제공하고자 하는 것이다.The present invention is to provide a new type 2 antidiabetic herbal drug with a clear hypoglycemic effect by supplementing the problems of the hypoglycemic experiment so far and ultimately improving insulin resistance.
본 발명은 2형 당뇨에 효능이 있는 생약제제에 관한 것으로서, 홍삼, 가시오가피, 동충하초의 잎·줄기 또는 뿌리의 추출물과 멀티-비타민을 주원료로 하고 홍삼, 가시오가피, 동충하초 추출물의 배합비를 달리하여 제조한 생약제제이다.The present invention relates to a herbal preparation that is effective in type 2 diabetes, and prepared by varying the ratio of the extracts of red ginseng, spiny ginseng, leaf, stem or root of Cordyceps sinensis and multi-vitamins, and the red ginseng, spiny ginseng, Cordyceps sinensis extract. It is a herbal medicine.
홍삼(Ginseng Radix rubra)은 인삼(Panax ginseng)을 껍질채 쩌서 말린것으로 주로 폐(肺)와 비(脾)에 작용하며, 대보원기요약(大補元氣要藥)으로 항 피로 및 항 스트레스 작용, 노화방지 작용, 간 기능 촉진 및 숙취제거효과, 항방사선작용, 정력증강, 항종양작용, 그리고 alloxan 투여에 의한 고혈당에 항당뇨작용이 있는 우리 나라의 대표적인 수출생약이다.Red ginseng ( Ginseng Radix rubra ) is a dried dried bark of Panax ginseng , which acts mainly on the lungs and the nasal air. Anti-aging, liver function and hangover elimination effect, anti-radiation effect, energetic enhancement, anti-tumor effect, and anti-diabetic effect of hyperglycemia by alloxan administration.
가시오가피나무(A.senticosus)는 인삼과 같은 오가과 (Araliaceae)의 식물로, 오가피나무속 식물의 근피와 수피를 五加皮(Acanthopanacis cortex)라 하여 주로 간(肝)과 신(腎)에 작용하는 생약으로, 면역기능 및 생체 저항력 강화작용, 정력증강과 학습력향상, 간기능 보전 및 해독작용, 구속수침 stress 위궤양 억제작용, 히스타민유리 억제작용, 항방사선작용, 심근경색 개선작용, 그리고 alloxan 투여에 의한 고혈당에 잎엑스의 saponin 분획이 혈당강하효과를 나타낸다.Gasiohgapi tree (A. Senticosus) is called to the herbal which mainly acts on the liver (肝) and the new (腎) of the plant of ohgagwa (Araliaceae), such as ginseng,五加皮the muscular fatigue and bark of Acanthopanax hawthorn plants (Acanthopanacis cortex) Increasing immune function and bio-resistance, enhancing energy and learning ability, preserving liver function and detoxification, restraint stress gastric ulcer, inhibiting histamine release, anti-radiation, improving myocardial infarction, and hyperglycemia by administration of alloxan Saponin fraction of leaf extract shows hypoglycemic effect.
또한, 동충하초(Cordyceps sinensis)는 예로부터 인삼, 녹용과 함께 귀한 3대 한방 약재로 취급되어 왔으며, 불로 장생의 비약으로 결핵, 황달 치료와 아편 중독의 해독제로 이용되어 온 생약이다.Cordyceps sinensis, along with ginseng and antler, has been treated as a precious three herbal medicines, and has been used as an antidote for tuberculosis, jaundice and opioid poisoning.
상기와 같이 홍삼, 가시오가피, 동충하초등은 그 고유의 약효가 이미 알려져 있는것이며, 항당뇨활성이 보고되었더라도, alloxan 이나 STZ 유발 고혈당에 의한 결과로서 제1형 당뇨모델에 가까운 것이었다. 그런데 본발명의 실험을 통해서 본발명의 생약제제가 대부분의 당뇨환자의 형태인 2형 당뇨병 치료에 효능이 있음을 확인되었다.As mentioned above, red ginseng, thorn stem, and Cordyceps sinensis are already known for their inherent effects, and even though antidiabetic activity has been reported, alloxan or STZ-induced hyperglycemia was close to the type 1 diabetes model. However, the experiment of the present invention confirmed that the herbal medicine of the present invention is effective in treating type 2 diabetes, which is the form of most diabetic patients.
본 발명에서 상기 선택된 약재추출물을 얻기 위하여 통상의 약재추출기를 이용하였다.In the present invention, a conventional medicinal herb extractor was used to obtain the selected medicinal herb extract.
추출용매로는 10-100 % 에타놀 또는 증류수를 선택하여 적용하였으나, 추출용매의 선택이 중요한것은 아니다. 따라서, 이하 실시예에서는 증류수 추출용매가 대표적으로 기재된다.Although 10-100% ethanol or distilled water was selected as the extraction solvent, the selection of the extraction solvent is not important. Therefore, distilled water extraction solvent is representatively described in the following examples.
약재추출공정은 선택된 모든 약재원료를 대상으로 하여 동일조건이 적용In the medicine extraction process, the same conditions apply to all selected medicine ingredients.
되며, 추출온도 30 내지 100℃ 및 추출시간 1-10시간을 적용하여 반복적 실험을 수행하였다. 여기에서 추출온도 및 추출시간의 변경은 본 발명의 기술분야에 관한 통상의 지식을 가진자에 의하여 용이하게 변경될 수 있는 실험조건이다.The experiment was repeated by applying an extraction temperature of 30 to 100 ℃ and an extraction time of 1-10 hours. Herein, the change of extraction temperature and extraction time is an experimental condition that can be easily changed by those skilled in the art.
본 발명의 추출물을 임상적인 목적으로 투여시에는 1일 1회 또는 2 내지 3회의 분리용량으로하고 숙주에게 투여될 총 일일용량은 체중 1kg 당 1 내지 50mg의 범위가 바람직하나, 특정 환자에 대한 특이 용량 수준은 사용될 특정 화합물, 체중, 연령, 성, 건강상태, 식이, 투여시간, 투여방법, 배설률, 약제혼합 및 질환의 중증도에 따라 변화될 수 있다.In the case of administering the extract of the present invention for clinical purposes, it is preferable to separate the dose once or two to three times a day and the total daily dose to be administered to the host is in the range of 1 to 50 mg per kg of body weight, but is specific for a specific patient. Dosage levels may vary depending on the specific compound to be used, weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, drug mixture and severity of the disease.
본 발명의 화합물은 목적하는바에 따라 주사제 또는 경구용 제제로 투여할 수 있다.The compounds of the present invention can be administered as injections or oral formulations as desired.
주사용 제제, 예를들면 멸균 주사용 수성 또는 유성 현탁액은 공지된 기술에 따라 적합한 분산제, 습윤제 또는 현탁제를 사용하여 제조할 수 있다. 이때, 사용될 수 있는 용매에는 물, 링거액 및 생리식염액이 있으며, 멸균 고정 오일은 통상적으로 용매 또는 현탁 매질로서 사용한다. 모노-, 디-글리세라이드를 포함하여 어떠한 무자극성 고정오일도 이러한 목적으로 사용될 수 있으며, 올레산과 같은 지방산도 주사용 제제에 사용할 수 있다.Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions, can be prepared using suitable dispersing agents, wetting agents or suspending agents according to known techniques. At this time, solvents that may be used include water, Ringer's solution and physiological saline solution, and sterile fixed oils are commonly used as a solvent or suspending medium. Any non-irritating fixed oil may be used for this purpose, including mono- and diglycerides, and fatty acids such as oleic acid may also be used in the preparation of injectables.
경구투여용 투여 형태는 캅셀제, 정제, 환제, 산제, 과립제 및 액제가 가능하고, 특히 캅셀제와 정제, 액제가 유용하다. 정제 및 환제는 장피제로 제조하는 것이 바람직하다. 고체 및 액체투여 형태는 본 발명에 따른 생약추출물을 슈크로오즈, 락토오즈, 전분 등과 같은 하나 이상의 불활성 희석제, 마그네슘스테아레이트, 탈크와 같은 윤활제, 칼슘 씨엠씨와 같은 붕해보조제, 결합제, 방향제, 소듐벤조에이트와 같은 방부제, 설탕 또는 과당과 같은 감미제 및 계면활성제 중에서 선택된 담체와 혼합하여 제조한다. 좀더 구체적으로 설명하면, 활성성분 이외에 부형제로서 전분과 유당을 7:3의 비율로 넣고 유동성 증대를 위하여 마그네슘 스테아레이트와 탈크를 3% 이내로 가하여 충진시킴으로써 캅셀제를 제조할 수 있고; 부형제로서 전분과 유당을 7:3의 비율로 넣고 결합제, 그리고 붕해보조제로 칼슘 씨엠씨를 가하여 타정함으로써 정제를 제조할 수 있으며; 방향제로 과일향, 방부제로 소듐벤조에이트, 감미제로 설탕 또는 과당 및 계면활성제를 첨가하여 액제를 제조할 수 있다.Dosage forms for oral administration may be capsules, tablets, pills, powders, granules, and solutions. Particularly, capsules, tablets, and solutions are useful. Tablets and pills are preferably prepared with enteric agents. Solid and liquid dosage forms can be used to prepare the herbal extracts according to the present invention with one or more inert diluents such as sucrose, lactose, starch, etc. It is prepared by mixing with a carrier selected from preservatives such as ate, sweeteners such as sugar or fructose and surfactants. More specifically, a capsule may be prepared by adding starch and lactose as an excipient in addition to the active ingredient in a ratio of 7: 3 and adding magnesium stearate and talc to within 3% to increase fluidity; Tablets can be prepared by adding starch and lactose as an excipient in a ratio of 7: 3 and adding calcium binder with a binder and a disintegration aid and tableting; A liquid preparation can be prepared by adding fruit flavor as a fragrance, sodium benzoate as a preservative, sugar or fructose as a sweetener and a surfactant.
본 발명은 선택된 약재를 추출하는 추출공정에서의 실험조건을 변경가능할 수 있으며, 상기 일반적인 제조공정조건은 본 발명의 약재추출물 선택에 부여된 발명에 영향을 미치지 아니한다.The present invention may change the experimental conditions in the extraction process of extracting the selected medicinal herbs, the general manufacturing process conditions do not affect the invention given to the selection of the medicinal extracts of the present invention.
따라서, 이하 실시예에서 명시된 추출공정 및 최종 생약제제 제조공정에서의 실시조건은 대표적인 수치만을 기재하는 것이며 이러한 수치 특정 및 한정은 본 발명인 조성물에 영향을 주지 아니한다.Therefore, the operating conditions in the extraction process and final herbal preparation manufacturing process specified in the following examples are only representative of the numerical values, and such numerical specification and limitation do not affect the composition of the present invention.
실시예Example
실시예 1Example 1
① 제1단계① First step
홍삼추출물의 제조Preparation of Red Ginseng Extract
홍삼을 증류수로 100℃에서 2시간 씩 2회 반복 추출하여, 감압농축하고 동결건조하여 홍삼추출물을 얻었다.Red ginseng was repeatedly extracted twice with distilled water at 100 ° C. for 2 hours, concentrated under reduced pressure and lyophilized to obtain red ginseng extract.
② 제2단계② Second step
가시오가피추출물의 제조Preparation of Prickly Pear Extract
가시오가피 줄기를 증류수 100℃에서 2시간 씩 2회 반복 추출하여, 감압농축하고 동결건조하여 가시오가피추출물을 얻었다.Prickly stems were repeatedly extracted twice at 100 ° C. for 2 hours, concentrated under reduced pressure and lyophilized to obtain thorny stem extracts.
③ 제3단계③ Third step
동충하초추출물의 제조Preparation of Cordyceps Sinensis Extract
동충하초를 증류수 100℃에서 2시간 씩 2회 반복 추출하여, 감압농축하고 동결건조하여 동충하초추출물을 얻었다.Cordyceps sinensis was repeatedly extracted twice at 100 ° C. for 2 hours, concentrated under reduced pressure, and lyophilized to obtain a cordyceps extract.
④ 제4단계④ 4th step
생약 멀티-비타민 혼합제제의 제조Preparation of herbal multi-vitamin blends
제1단계에서 얻은 홍삼추출물 20∼80 중량%와 제2단계에서 얻은 가시오가피추출물 80∼20 중량% 그리고 제3단계에서 얻은 동충하초 1∼5 중량%를 혼합하고 일정양[Vitamin (B10.046 중량%, B20.046 중량%, B60.046 중량%, B120.002 중량%, C 2.3 중량%, E 0.46 중량%)의 멀티-비타민을 추가혼합하였다.20 to 80% by weight of the red ginseng extract obtained in the first step, 80 to 20% by weight of the bark extract extracted in the second step, and 1 to 5% by weight of the Cordyceps sinensis obtained in the third step, were mixed [Vitamin (B 1 0.046% by weight) , B 2 0.046 wt%, B 6 0.046 wt%, B 12 0.002 wt%, C 2.3 wt%, E 0.46 wt%) multi-vitamin.
상기 제4단계에서의 혼합비율은 홍삼추출물 69.4 중량%와 가시오가피추출물 23.1 중량%와 동충하초 4∼6 중량%일 수 있다.In the fourth step, the mixing ratio may be 69.4% by weight of red ginseng extract, 23.1% by weight of thorny oocyte extract, and 4-6% by weight of Cordyceps sinensis.
상기 실시예에서 선택된 가시오가피 줄기를 대신하여 잎 또는 뿌리를 선택하여 적용할 수 있다.In the above embodiment can be applied to select the leaves or roots in place of the selected stems.
본 발명은 가시오가피추출물이 가시오가피 어느 부분에서 채취된 것인가는 본 발명의 효과를 좌우하는 중요인자가 될 수 없는 것이다. 따라서, 이하 가시오가피 추출물이라 함은 가시오가피의 잎, 줄기 또는 뿌리에서의 추출물을 언급하는 것이며, 이는 가시오가피 추출물과 관련된 반복적인 실험으로부터 확인된 사실에 기초한 것이다.In the present invention, which part of the prickly pear extract is collected is not an important factor that determines the effect of the present invention. Thus, thorny thorns extract refers to extracts on the leaves, stems or roots of thorny thorns, based on the facts identified from repeated experiments involving thorny thorns.
본 발명은 상기 실시예를 통하여 명시한 바와 같이 항2형 당뇨효과를 얻기 위하여 홍삼 추출물 및 가시오가피수피로 대표되는 가시오가피 추출물 또는 동충하초 추출물을 여러 방법으로 제조할 수 있다. 그러나, 상기 제시한 추출 방법은 각각의 생약의 혼합후 용매추출에 국한되지 아니한다.The present invention can be prepared by a number of methods to extract the extract of the thorny scabies or Cordyceps sinensis, which are represented by the red ginseng extract and thorny bark bark in order to obtain the anti-type 2 diabetes effect as described in the above examples. However, the extraction method presented above is not limited to solvent extraction after mixing each herbal medicine.
또한, 최종추출물의 존재상태는 액상 또는 분말의 어떠한 형태일 수도 있다.In addition, the presence state of the final extract may be in any form of liquid or powder.
본 발명의 분명한 효과인 2형 당뇨로 인한 고혈당 저하를 위한 선택된 약재 및 이들의 조성비율은 홍삼 추출물 20∼80 중량%, 가시오가피 추출물 80∼20 중량%Selected medicinal herbs and their composition ratio for hyperglycemic lowering due to type 2 diabetes, which is an obvious effect of the present invention, 20 to 80% by weight of red ginseng extract, 80 to 20% by weight of prickly pear extract
, 동충하초 추출물 1∼5 중량% 이며, 가장 바람직하게는 홍삼 추출물 60∼70 중량%, Cordyceps sinensis extract 1 to 5% by weight, most preferably red ginseng extract 60 to 70% by weight
, 가시오가피 추출물 20∼30 중량%, 동충하초 추출물 1∼5 중량%이다., 20-30% by weight of thorny thorns extract, 1-5% by weight of Cordyceps sinensis extract.
실험예 1Experimental Example 1
2형 당뇨 실험Type 2 diabetes experiment
제2형 당뇨 질환모델로서 KKAY마우스에 대하여 홍삼, 가시오가피, 동충하초 단독 및 혼합추출물 또한, 멀티-비타민 혼합추출물을 경구투여하기전과 1달간 경구투여후의 공복시 혈당(fasting blood glucose)을 비교검토한 후 (2000. 8. 30 경구투여후 2000. 9. 26일 혈당량 측정) 혈당상승에 대한 시료용액의 억제작용은 하기 수학식 1에 따라 대조군의 경구투여전과 경구투여후의 혈당량 차에 대한 각 시료군의 비로부터 각 시료군의 억제율을 구하여 평가하였다.As a type 2 diabetes model, KKA Y mice were compared with fasting blood glucose before and after oral administration of red ginseng, spiny ginseng, Cordyceps sinensis and mixed extracts, or multi-vitamin mixed extracts. (Measurement of blood glucose level after oral administration on August 30, 2000) The inhibitory effect of the sample solution on the blood glucose increase was determined in each sample group for the difference in blood glucose levels before oral administration and after oral administration of the control group according to Equation 1 below. The inhibition rate of each sample group was calculated | required from ratio, and it evaluated.
결과는 표 1.과 같다.The results are shown in Table 1.
표 1. 14시간 공복후의 혈당량 및 혈당상승 억제율Table 1. Glucose and Glucose Inhibition Rate after 14-Hour Fasting
A : 홍삼 (300 ㎎/㎏)A: red ginseng (300 mg / kg)
B : 가시오가피 (300 ㎎/㎏)B: visiogapi (300 mg / kg)
C : 동충하초 (300 ㎎/㎏)C: Cordyceps sinensis (300 mg / kg)
D : 홍삼 (300 ㎎/㎏) + 가시오가피 (100 ㎎/㎏) + 동충하초 (20 ㎎/㎏)D: Red ginseng (300 mg / kg) + thorn ogapi (100 mg / kg) + Cordyceps sinensis (20 mg / kg)
E : 홍삼 (300 ㎎/㎏) + 가시오가피 (100 ㎎/㎏) + 동충하초 (20 ㎎/㎏) + Vitamin (B10.2mg/kg, B20.2mg/kg, B60.2mg/kg, B120.2㎍/kg, C 10mg/kg, E 2mg/kg)E: Red ginseng (300 mg / kg) + thorny ogapi (100 mg / kg) + Cordyceps sinensis (20 mg / kg) + Vitamin (B 1 0.2mg / kg, B 2 0.2mg / kg, B 6 0.2mg / kg, B 12 0.2 μg / kg, C 10 mg / kg, E 2 mg / kg)
상기 표 1에 기재된 수치는 6회 실험하여 얻은 평균치이고, "*"는 P < 0.05 인 것을 의미한다.The numerical value shown in Table 1 above is an average value obtained by six experiments, and " * " means that P <0.05.
표 1.에서 보는 바와같이, 홍삼, 가시오가피, 동충하초의 각 추출물과 각 추출물 혼합엑스 및 각 추출물 혼합엑스와 Vitamine 혼합엑스를 대상으로 2형 당뇨모델인 KKAY고혈당 흰쥐에 대하여 1달간의 경구투여 결과 공복시 혈당이 홍삼, 가시오가피, 동충하초의 단독 추출물 중에서는 가시오가피 추출물만 50.3 %의 유의성 있는 혈당상승 억제효과를 나타내었으나, 홍삼, 가시오가피, 동충하초의 추출물 혼합엑스와 Vitamine 혼합엑스가 75.6 %와 73.5 %의 보다 강한 혈당상승 억제율을 나타내었다. 이와 같은 결과는 홍삼, 가시오가피, 동충하초와 Vitamine을 혼합하므로 서 단독투여의 경우와 달리 병용상승효과를 나타내는 것이 확인되었다. 한편 양성대조약물인 Rosiglitazone도 80.6 %의 강한 혈당상승 억제효과를 나타내었다.As shown in Table 1. Results of 1 month oral administration of KKA Y hyperglycemic rats, type 2 diabetes model, for each extract, extract extract and extract extract of red ginseng, prickly pear, Cordyceps sinensis Fasting blood glucose showed a significant inhibitory effect of 50.3% of the extracts of red ginseng, barberry, and Cordyceps sinensis, but the extracts of red ginseng, barberry, and Cordyceps were higher than 75.6% and 73.5%. It showed strong blood sugar rise inhibition rate. These results were confirmed to show a synergistic effect, unlike the case of single administration by mixing red ginseng, prickly pear, cordyceps and Vitamine. Rosiglitazone, a positive control drug, also showed a strong inhibitory effect on blood glucose elevation of 80.6%.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0062697A KR100376030B1 (en) | 2000-10-24 | 2000-10-24 | crude drug for 2type diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-0062697A KR100376030B1 (en) | 2000-10-24 | 2000-10-24 | crude drug for 2type diabetes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020031911A true KR20020031911A (en) | 2002-05-03 |
KR100376030B1 KR100376030B1 (en) | 2003-03-15 |
Family
ID=19695195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0062697A KR100376030B1 (en) | 2000-10-24 | 2000-10-24 | crude drug for 2type diabetes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100376030B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030089864A (en) * | 2002-05-20 | 2003-11-28 | 이재수 | Tonic |
KR100523443B1 (en) * | 2002-08-19 | 2005-10-25 | 주식회사 엠디바이오알파 | Active extracts from natural plants showing anti-obesity and anti-diabetes |
KR100685472B1 (en) * | 2004-04-20 | 2007-02-23 | 주식회사 유유 | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome |
KR100697184B1 (en) * | 2006-01-06 | 2007-03-21 | 주식회사 농협고려인삼 | A functional food for a ginseng and mulberry and banaba and the producing method therof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101275375B1 (en) * | 2011-06-16 | 2013-06-17 | 동아대학교 산학협력단 | Manufacturing Method of Cordyceps militaris Extracts And Health Assistance Food Comprising the Extracts |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06237735A (en) * | 1993-02-15 | 1994-08-30 | Nitto Denko Corp | Food having hypoglycemic action |
US5560967A (en) * | 1994-07-25 | 1996-10-01 | The Excello Specialty Company | Sound absorbing automotive water deflector |
KR100195886B1 (en) * | 1996-11-01 | 1999-06-15 | 김상조 | Pharmaceutical composition for treating diabetes mellitus |
JPH10245341A (en) * | 1997-03-04 | 1998-09-14 | Meiji Milk Prod Co Ltd | Hypoglycemic composition |
KR20010100733A (en) * | 2000-05-06 | 2001-11-14 | 박태웅 | Manufacturing method of red ginseng cordyceps |
KR101243718B1 (en) * | 2011-03-18 | 2013-03-13 | (주)엔탑스 | drainage pumping apparatus |
-
2000
- 2000-10-24 KR KR10-2000-0062697A patent/KR100376030B1/en not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030089864A (en) * | 2002-05-20 | 2003-11-28 | 이재수 | Tonic |
KR100523443B1 (en) * | 2002-08-19 | 2005-10-25 | 주식회사 엠디바이오알파 | Active extracts from natural plants showing anti-obesity and anti-diabetes |
KR100685472B1 (en) * | 2004-04-20 | 2007-02-23 | 주식회사 유유 | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome |
KR100697184B1 (en) * | 2006-01-06 | 2007-03-21 | 주식회사 농협고려인삼 | A functional food for a ginseng and mulberry and banaba and the producing method therof |
Also Published As
Publication number | Publication date |
---|---|
KR100376030B1 (en) | 2003-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Verma et al. | Diabetes mellitus treatment using herbal drugs | |
Nyunaï et al. | Hypoglycaemic and antihyperglycaemic activity of Ageratum conyzoides L. in rats. | |
KR101090319B1 (en) | A composition having an effect of curing and preventing diabetes mellitus | |
EP1013278B1 (en) | The extract of pine needle and the use thereof | |
CN108186877A (en) | For the Chinese medicine composition of syndrome of blood stasis due to qi deficiency myocardial infarction secondary prevention | |
KR100831621B1 (en) | The plant extracts composition for the blood glucose reducing action | |
Njike et al. | Hypoglycaemic activity of the leaves extracts of Bersama engleriana in rats. | |
Munyangi et al. | Five case reports on treatment of diabetes by Artemisia annua and Artemisia afra herbal tea | |
KR101094157B1 (en) | The health food for improvement of glucosuria using madisin-materials of plants | |
KR100376030B1 (en) | crude drug for 2type diabetes | |
CN106798854B (en) | Phyllanthus emblica leaf and preparation method thereof | |
KR20090126469A (en) | The herb extract composition for the blood glucose reducing action | |
KR20230019510A (en) | Red Ginseng Bokryeong Containing Aronia 6.0 BRIX Effective for Diabetes | |
Thallaj et al. | Studying the efficacy of the plant extract of Tetracera scandens as an antidiabetic treatment | |
Kamala et al. | Anti–Hyperglycemic and Anti–Hyperlipidemic Potentials of Psidium guajava Fruit Extract–a Review | |
RU2114628C1 (en) | Component composition "adaptovit" showing antihypoxic effect | |
CN108186799A (en) | Ground bone slender acanthopanax dissipates and preparation method | |
Konsue et al. | Effect of Thai folklore recipe from Abutilon indicum and Mimosa pudica in streptozotocin-induced diabetic rats | |
KR100697632B1 (en) | Pharmaceutical compositions and functional food comprising Extract of Mixture of Crude Medicine | |
KR20040036992A (en) | Extracting method of extract from Protaetia brevitarsis grub and pharmaceutical composition for diabetes treatment containing the extract | |
RU2805492C1 (en) | Method for correction of post-prandial glycemia | |
Nwoke et al. | Comparative antihyperglycemic potentials of different fractions of Detarium senegalense stem bark extract on streptozotocin-induced diabetic Wistar rats | |
RU2805492C9 (en) | Method for correction of post-prandial glycemia | |
KR20030059952A (en) | Composition containing an extract of truncated sopungsungi-won crude drug complex for preventing and treating diabetes | |
CN106344780A (en) | Traditional Chinese medicinal composition having blood glucose reducing effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20100302 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |